His health, he said, shifted dramatically: no more sleep apnea, no more blood-pressure meds, a healthier liver
Compounded Tirzepatide Compounded Semaglutide Same active ingredient as Ozempic & Wegovy GLP-1 receptor agonist (single target) Average weight loss: ~15% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Well-studied safety profile Good starting option for most patients Compounded Tirzepatide Same active ingredient as Mounjaro & Zepbound Dual GLP-1 + GIP receptor agonist Average weight loss: up to 21% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Additional blood sugar regulation via GIP pathway May be more effective for patients with insulin resistance Not sure which is right for you
Dose: 2 mg (2000 mcg) daily after Week 1 titration
According to a new Gallup survey, 11% of US adults now take GLP-1 drugs specifically for weight loss, up from 3% in 2024
It also gives you more power to stay on track as you go through your weight loss journey
The headline claims LifeVantage reports the following results from their clinical research: 200%+ average increase in GLP-1 levels Average weight loss of 11 pounds in 12 weeks, with some participants losing up to 25 pounds 100% of participants who lost weight maintained muscle mass Up to 6% total body fat percentage lost Up to 24% visceral fat reduction 86% decreased food, salt, and soda cravings 95% decreased sugar cravings 89% decreased fast food cravings These numbers look impressive at first glance